skip to Main Content

Navigating Value-Based Care, Defining Value, and Drug Pricing Policy

  • This page as PDF


Join Avalere for a live discussion on key trends in drug pricing, value, and regulatory shifts, and how these trends will impact manufacturers.

Following our annual Healthcare Industry Outlook webinar, we surveyed 1,400 healthcare stakeholders and found that life sciences companies are prioritizing 3 key initiatives moving into 2022:

  • Value-based approaches to care, including quality and performance management
  • Defining and demonstrating value of drugs
  • Legislative and regulatory efforts related to drug pricing

In our spring 2022 Life Sciences Perspective, Avalere experts took a deeper look into these topics and how they may impact your business as we move into Q2.


Elizabeth Carpenter , President

As president of Avalere Health, Elizabeth Carpenter is responsible for the firm’s consulting, sales, and operational functions.

Panel 1: Value-based approaches to care including quality & performance management

Guest Speaker
Tricia Marine Barrett, MHSA Executive Director of Quality and Population Health Strategy, Bayer Pharmaceuticals

Panel 2: Approaches to defining & demonstrating value of drugs

Guest Speaker
Daniel C. Lane, PharmD, PhD, MBA Director, US Access Marketing-Customer & Portfolio Value Generation, Bristol Myers Squibb
Sarah Alwardt Senior Vice President
Evidence & Strategy
Milena Sullivan Managing Director

Panel 3: Legislative & regulatory efforts related to drug pricing

Matt Kazan Managing Director
Lance Grady Practice Director
Market Access & Reimbursement
From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about Value-Based Care
Please enter your email address to be notified when new Value-Based Care insights are published.

Back To Top